Navigation Links
New Strategy to Counter Problem Drinking

Problem drinkers who took a craving-curbing drug whenever they felt the desire to imbibe reported fewer heavy drinking days each month than drinkers who took a look-alike placebo pill, but both groups reported marked reductions in heavy drinking days.

Those findings come from a study of 403 heavy drinkers in Finland, who took either a placebo or the drug nalmefene on an as needed basis.

It has a robust and sustained effect in reducing harmful heavy drinking in a large study population, said researcher Sakari Karhuvaara. Alcohol problems have huge negative impacts on the well-being of individuals and families and cause enormous costs to society due to lost working days, accidents, treatment of alcohol-related disease, etcetera.

Before the study, patients assigned to nalmefene treatment reported 15.5 average heavy drinking days each month. They were directed to take the drug whenever they felt a looming urge to drink. During the first three months of treatment, the average number of heavy drinking days was 8.6 to 9.3 for the people in the nalmefene group.

The drinkers assigned to the placebo group had somewhat less dramatic reductions. They averaged 16.2 heavy drinking days a month before the study and 10.6 to 12.0 during the trial.

Researchers double-checked participant-reported alcohol consumption changes with tests that measured alcohol-use biomarkers in the blood.

In the United States, abstinence has been the traditional goal of the treatment of alcohol dependence, but in the last 20 years, there has been a movement to consider harm reduction or drinking reduction as a goal equal to abstinence.

Alcohol dependence is nowadays recognized as a chronic, recurring disorder where relapses almost inevitably occur during and after the treatment, Karhuvaara said. So focusing on harm reduction in the short term is often much more feasible than complete abst inence, he added.

Karhuvaara is a physician and health researcher who was once an employee of Biotie Therapies Corp., the manufacturer of nalmefene. The drug maker supported the new study.

There are fair amounts of good data (showing) that the more drinks you have a day, the more likely you are to have health or social consequences, said alcohol researcher Raymond Anton.

The thinking is that if you can reduce heavy drinking days or the number of drinks per drinking day, you might actually alleviate some suffering, even though you dont cause the person to be abstinent.

Not everyone who seeks alcohol treatment is ready to consider a lifetime without alcohol, so an abstinence goal can be a barrier for some people considering help.

Many health professionals are convinced that a harm reduction approach can draw more people into treatment, said Anton, director of the Center for Drug and Alcohol Programs at the Medical University of South Carolina. Anton did not participate in the Finnish study, but he has conducted nalmefene research in the United States.

The Finnish researchers note some side effects among people in the nalmefene group, including nausea, abdominal discomfort, as well as energy and sleep difficulties. However, most study participants remained in the trial and continued using the drug.

I wish theyd done an analysis to see if the people who suffered those side effects were the same people who drank less. Perhaps some of the reduction in drinking may have been because they didnt feel so good, rather than because the drug just took away an urge to drink, Anton said.

Patients must take most medications for alcohol treatment daily. Nalmefene taken as needed fits into the harm reduction treatment approach.

The drug is an opioid antagonist that works to block the effects of endorphins. The U.S. Food and Drug Administrat ion has not approved nalmefene for use in alcohol treatment; the drug is primarily available in investigational studies.

Karhuvaara said his study also suggests that practically any doctor could successfully administer nalmefene in a wide variety of medical settings.

It is an attempt to get the drug out of the sole use of addiction specialists and into the hands of primary providers, Anton said.


Related medicine news :

1. Novel Strategy To Combat Alzheimer’s Disease
2. "Defensive Pessimism" Before Exam Results Not a Good Strategy
3. WHO Devises New Global Strategy To Fight Tuberculosis
4. HER-2 Positive Breast Cancer Patients May Benefit With a Combo Drug Strategy
5. West Nile Virus Can Be Tackled By New Strategy
6. Australia Set To Implement A national Strategy Tackle Cannabis Abuse
7. Clement Urged to Plot a National Pharmaceutical Strategy
8. New Preventive Strategy to Fight Childhood Obesity
9. Rae unveils Health-care Strategy
10. A Promising New Vaccination Strategy for Late-Stage Melanoma
11. Effective Strategy Against Bird flu-Spainish Flu Vaccine Raises Hopes
Post Your Comments:

(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions ... SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of ... SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment ... itself for not only fulfilling the needs of advisers and clients but going ... price and providing top-tier customer service. However, there's always room for improvement, which ...
(Date:11/27/2015)... ... 2015 , ... CBD College is proud to announce that on ... accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join this ... colleges and universities in the state of California make the cut. CBD College is ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Dr. ... Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., ... observed that both STEMI and Sepsis conditions present in similar ways and require time-critical ...
(Date:11/27/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class ... (Long Term Support) into its Q-Suite 5.10 product line. , Making the change ... version of Asterisk that will receive not only security fixes, but feature and ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/25/2015)... WILMINGTON, N.C. , Nov. 25, 2015 /PRNewswire/ ... announces the planned investment of at least $15.8 ... in Wilmington, NC . The ... services capacity to meet the growing demands of ... Wilmington site expansion will provide up ...
Breaking Medicine Technology: